PharmaFocus: Tauopathies–Global Market Analysis
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Tauopathies are a class of more than 20 neurodegenerative diseases characterized by tau protein aggregation in the brain. There are currently no treatments approved in this therapy area and five tauopathies are attracting increasing attention from pharmaceutical companies in particular. These are: progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), Pick’s disease (clinically referred to as bvFTD), and chronic traumatic encephalopathy (CTE). In these indications, symptoms often present as behavioral (e.g. disinhibition, apathy), cognitive (e.g. memory loss), language (e.g. slurring of speech), or motor (e.g. falls, tremor) deficits. A multitude of treatments are used off-label to alleviate patients’ symptoms and they include those indicated for Parkinson’s disease, Alzheimer’s disease, or depression. Growth in tauopathies market is likely to be driven by the introduction of novel treatments into the market while continued lack of quantitative biomarkers will be a major barrier to the growth of the tauopathies market.
Scope
Overview of tauopathies including, etiology, pathophysiology, symptoms, diagnosis, and clinical trial challenges.
Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the tauopathy therapeutics market.
Pipeline analysis: focus on four late-stage pipeline tauopathy drugs, discussing emerging trends as well as an overview of earlier phase and preclinical drugs.
Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Key Highlights
The report will enable you to:
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
Develop business strategies by understanding the trends shaping and driving the global tauopathy therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global tauopathy therapeutics market in future.
Formulate effective sales and marketing strategies by understanding the competitive landscape.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Key Questions Answered
The tauopathies market is in its infancy with limited choices of symptomatic treatments being offered off-label. In light of this, what are the current clinical and environmental unmet needs? Will there be opportunities in this market for drug developers in the near future?
There are five substantial unmet needs that exist in the tauopathies market. Will pipeline drugs fulfil any of the unmet needs for tauopathies? Which unmet needs will provide opportunity for drug developers?
Four products are currently in late-stage of development. What unmet needs will these drugs fulfil? How will they affect the treatment algorithm for tauopathy patients?
Many challenges exist for companies entering the tauopathies market. What are the key challenges involved in clinical trials? What strategies are companies using to enter the tauopathies market?"
AB Science
Alectos Therapeutics
AlzProtect
Anavex Life Sciences
Asceneuron
Avanir Pharmaceuticals
Biogen
Brighton Biotech
Bristol-Myers Squibb
Catalent
Cortice Biosciences
C2N Diagnostics
Déclion Pharmaceuticals
Delta Crystallon
Eli Lilly
Gismo Therapeutics
GSK
Intellect Neurosciences
Kannalife Sciences
Merck & Co.
Neurimmune Holding
Otsuka
Pfizer
Prana Biotechnology
PresSura Neuro
Sellas Lifesciences Group
TauRx Pharmaceuticals
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.